We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
226
Bank of Montreal
Ontario, Canada
$169K +$53.7K +1,353 +69%
DVF
227
Discovery Value Fund
Singapore
$164K +$141K +3,544 New
NICM
228
Neo Ivy Capital Management
New York
$142K +$61.5K +1,549 +102%
Pacer Advisors
229
Pacer Advisors
Pennsylvania
$123K -$36.4K -916 -26%
FF
230
FourThought Financial
Florida
$101K +$87.3K +2,198 New
AA
231
AlphaCentric Advisors
Puerto Rico
$93K +$33.7K +850 +74%
Parallax Volatility Advisers
232
Parallax Volatility Advisers
California
$45K -$325K -8,176 -89%
LFG
233
Larson Financial Group
Missouri
$37K – – –
CAPTRUST Financial Advisors
234
CAPTRUST Financial Advisors
North Carolina
$32K – – –
ACA
235
Atlas Capital Advisors
Wyoming
$30.2K +$25.8K +650 New
SFS
236
Sowell Financial Services
Arkansas
$28K +$1.19K +30 +5%
Rockefeller Capital Management
237
Rockefeller Capital Management
New York
$23K -$16.4K -412 -45%
NFG
238
Next Financial Group
Texas
$19K – – –
PNC Financial Services Group
239
PNC Financial Services Group
Pennsylvania
$16K +$596 +15 +5%
RE
240
RBC Europe
United Kingdom
$13.7K – – –
Daiwa Securities Group
241
Daiwa Securities Group
Japan
$13K -$21.6K -543 -66%
Loomis, Sayles & Company
242
Loomis, Sayles & Company
Massachusetts
$13K +$11K +277 New
GWS
243
Glassman Wealth Services
Virginia
$12K +$9.93K +250 New
BCA
244
Berman Capital Advisors
Georgia
$7K -$675 -17 -10%
BAM
245
Bellevue Asset Management
Washington
$6K -$1.63K -41 -25%
OSAM
246
O'Shaughnessy Asset Management
Connecticut
$5K – – –
EI
247
Ellevest Inc
New York
$3K +$397 +10 +22%
QCG
248
Quadrant Capital Group
Ohio
$3K +$1.23K +31 +91%
IA
249
IFP Advisors
Florida
$3K +$1.99K +50 +333%
RPWA
250
Regent Peak Wealth Advisors
Georgia
$3K +$2.3K +58 New
8 9
10
11 12

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.